Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers

Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2010, Pages 50-61

  Kienzler, Jean Luc ^a   Gold, Morris ^b   Nollevaux, Fabrice ^c  

^a Department of Clinical Pharmacology   (Switzerland)

^b Novartis Consumer Health   (United States)

^c SGS Life Science Services   (Belgium)

Author keywords

Absorption; Bioavailability; Diclofenac; Pharmacodynamics; Pharmacokinetics

Indexed keywords

4' HYDROXYDICLOFENAC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DRUG METABOLITE; PROSTAGLANDIN E2; THROMBOXANE B2; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PARESTHESIA; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG EXPOSURE; DRUG URINE LEVEL; DYSPEPSIA; ENZYME INHIBITION; ERUCTATION; FEMALE; GEL; HAND; HUMAN; KNEE; MALE; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TABLET; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DICLOFENAC; DINOPROSTONE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; TABLETS, ENTERIC-COATED; THROMBOXANE B2;

EID: 72749102021     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009336234     Document Type: Article

References (34)

1. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000 ; 43: 1905-1915.
2. Jordan KM, Arden NK, Doherty M., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003 ; 62: 1145-1155. (Pubitemid 37500619)
3. Pendleton A., Arden N., Dougados M., et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2000 ; 59: 936-944.
4. Zhang W., Doherty M., Leeb BF, et al. EULAR evidence based recommendations for the diagnosis of hand osteoarthritis-report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007 ; 66: 377-388.
5. Zhang W., Moskowitz RW, Nuki G., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007 ; 15: 981-1000.
6. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem. 1999 ; 274: 22903-22906.
7. Dannhardt G, Kiefer W. Cyclooxygenase inhibitors: current status and future prospects. Eur J Med Chem. 2001;36:109-126. 8. Lo V, Meadows SE, Saseen J. When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis? J Fam Pract. 2006;55:260-262.
8. Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006 ; 29: 621-632.
9. Singh G., Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998 ; 51: 8-16.
10. Tannenbaum H., Bombardier C., Davis P., et al. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol. 2006 ; 33: 140-157.
11. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999 ; 106 (5B). 13S - 24S.
12. Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin. 2007 ; 23: 2985-2995.
13. Heyneman CA, Lawless-Liday C., Wall GC Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000 ; 60: 555-574.
14. Moore N. Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clin Drug Investig. 2007 ; 27: 163-195.
15. Zacher J., Altman R., Bellamy N., et al. Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin. 2008 ; 24: 925-950.
16. Magnette JL, Kienzler JL, Sallin D., et al. Diclofenac systemic exposure is not increased when topical diclofenac is applied to ultraviolet-induced erythema. Eur J Clin Pharmacol. 2004 ; 60: 591-594.
17. Tugwell PS, Wells GA, Shainhouse JZ Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004 ; 31: 2002-2012.
18. Zacher J., Burger K., Farber L., et al. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden?s and/or Bouchard?s nodes): double-blind, controlled, randomized study. Aktuel Rheumatol. 2001 ; 26: 7-14.
19. Voltaren Gel 1%. Parsippany, NJ: Novartis Consumer Health; 2007.
20. Kinlough-Rathbone R., Packham M., Mustard J. Platelet aggregation. In: Harder L, Zimmerman T, eds. Measurements of Platelet Function: Methods in Hematology. London: Churchill Livingstone ; 1983: 64-91.
21. Machin S., Mackie I. Platelet function tests. In: Chanarin I, ed. Laboratory Haematology: An Account of Laboratory Techniques. London: Churchill Livingstone; 1989: 371-389.
22. Baraf H, Ramsay AJ, Schumacher D, et al. Long-term safety of diclofenac sodium gel 1% in patients with osteoarthritis of the knee [poster 430]. Presented at the 2007 World Congress on Osteoarthritis, Ft. Lauderdale, FL, USA, December 6-9, 2007. Osteoarthritis Cartilage. 2007;15(suppl C):C233.
23. Sioufi A., Pommier F., Boschet F., et al. Percutaneous absorption of diclofenac in healthy volunteers after single and repeated topical application of diclofenac Emulgel. Biopharm Drug Dispos. 1994 ; 15: 441-449.
24. Rolf C., Engstrom B., Beauchard C., et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford). 1999 ; 38: 564-567.
25. Reilly IA, FitzGerald GA Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987 ; 69: 180-186.
26. Altman R, Longley S, Rachidi S. Topical diclofenac sodium gel for knee osteoarthritis [poster 415]. Presented at the 2007 World Congress on Osteoarthritis, Ft. Lauderdale, FL, USA, December 6-9, 2007. Osteoarthritis Cartilage. 2007;15(suppl C):C225.
27. Altman R., Zacher J., Dreiser RL Efficacy and safety of diclofenac sodium gel 1% in patients with OA of the hand: a prospective, 8-week, randomized, double-blind, vehicle-controlled, multicenter, phase 3 trial [poster 288]. Presented at: American College of Rheumatology Annual Meeting ; November 6-11, 2007 ; Boston, MA.
28. Barthel HR, Haselwood D., Parikh P., et al. Efficacy and safety of diclofenac sodium gel 1% in patients with OA of the knee: a prospective, 12-week, randomized, double-blind, vehicle-controlled, multicenter, phase 3 trial [poster 289]. Presented at: American College of Rheumatology Annual Meeting ; November 6-11, 2007 ; Boston, MA.
29. Cronstein BN Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med. 2002 ; 69: S13 - S19.
30. Huntjens DRH, Danhof M., Della Pasqua OE Pharmacokineticpharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology. 2005 ; 44: 846-859.
31. Lipsky LPE, Abramson SB, Crofford L., et al. The classification of cyclooxygenase inhibitors. J Rheumatol. 1998 ; 25: 2298-2303.
32. Cryer B., Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 ; 104: 413-421.
33. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001 ; 345: 433-442.
34. Patrignani P., Panara MR, Greco A., et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994 ; 271: 1705-1712.